期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 137, 期 2, 页码 358-368出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2015.12.1300
关键词
International consensus; allergy; immunotherapy; allergen vaccine; allergen standardization; pharmacoeconomics; cost-effectiveness; mechanisms; tolerance; marketing authorization; regulatory authorities; unmet needs
资金
- Anergis
- Allergopharma
- GLG Research (Gerson Lehrman Group)
- ActoGeniX
- Genentech
- Sanofi US Services
- Valeant Pharmaceuticals North America
- ALK-Abello
- Stallergenes
- Merck
- Greer
- Circassia
- Stallergenes-Greer
- DBV
- Thermo Fisher Scientific
- Chiesi
- Pierre Fabre Medicament
- Menarini
- MSD
- AstraZeneca
- NIHR (UK)
- MEDA
- Pfizer
- MIT
- BI
- Novartis Glenmark
- Novartis
- UCB
- GlaxoSmithKline
- Astra Zeneca
- Senosiain
- Sanofi
- TEVA
- Carnot
- Glenmark
- Mylan
- Pharma Dynamics
- INNOVA Pharma
- Medical Research Council of South Africa
- Thermo Fisher
- GlaxoSmithKline/Aspen
- Cipla
- Astellas
- Beiersdorf
- Takeda Nycomed
- Pearl Therapeutics
- Allergopharma (Germany)
- ALK-Abello (Denmark)
- Stallergenes (France)
- HAL-Allergy (Netherlands)
- Artu Biologicals (Netherlands)
- Allergy Therapeutics/Bencard (United Kingdom/Germany)
- Hartington (Spain)
- Lofarma (Italy)
- Novartis/Leti (Germany/Spain)
- GlaxoSmithKline (United Kingdom)
- Essex-Pharma (Germany)
- Cytos (Switzerland)
- Curalogic (Denmark)
- Roxall (Germany)
- Biomay (Austria)
- Thermo Fisher (United States)
- Circassia (United Kingdom)
- E.U
- Biotech Tools (Belgium)
- MEDA-Pharma (Sweden)
- Anergis (Switzerland)
- Bencard (Germany)
- Novartis/LETI (Germany)
- MEDA-Pharma (Germany)
- GfK Bridgehead (United Kingdom)
- NAVIGANT-consulting (United States)
- Sanofi (United States)
- Guide-point Global Advisors (United States)
- Pohl-Boskamp (Germany)
- Mobile Chamber Experts (a GA2LEN partner, Germany)
- HAL-Allergy (Germany/Netherlands)
- GlaxoSmithKline (Germany)
- Thermo-Fisher (Germany)
- Schattauer (Germany)
- Springer (Germany)
- European Academy of Allergy and Clinical Immunology (EAACI)
- German Society for Allergology and Clinical Immunology (DGAKI)
- German Respiratory Society (DGP)
- European Commission
- Scientific Advisory Board Chair for HAL Allergy BV
- Bayer CropScience
- National Institute of Allergy and Infectious Diseases (NIAID) [NO1-AI-15416, UM1AI109565]
- Food Allergy and Research Education (FARE)
- UK Department of Health through NIHR
- HAL
- Crucell
- Emerade
- NOW
- STW
- Biomay
- Actelion
- Aventis
- Circacia
- PREDICTA (European Commission's Seventh Framework programme) [260895]
- Swiss National Science Foundation
- MeDALL (European Commission's Seventh Framework Programme) [261357]
- Christine Kuhne-Center
This article continues the comprehensive international consensus (ICON) statement on allergen immunotherapy (AIT). The initial article also recently appeared in the Journal. The conclusions below focus on key mechanisms of AIT-triggered tolerance, requirements in allergen standardization, AIT cost-effectiveness, and regulatory guidance. Potential barriers to and facilitators of the use of AIT are described in addition to future directions. International allergy specialists representing the European Academy of Allergy and Clinical Immunology; the American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma and Immunology; and the World Allergy Organization critically reviewed the existing literature and prepared this summary of recommendations for best AIT practice. The authors contributed equally and reached consensus on the statements presented herein.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据